Paricalcitol

Generic Name: Paricalcitol

Brand Names: Zemplar

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₄O_₃

CAS Number: 131918-61-1

Unique Ingredient Identifier: 6702D36OG5

Background: Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Indication: For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4

Associated Conditions: Secondary Hyperparathyroidism (SHPT)

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism Due to Renal Causes

Interventions: Drug: Calcifediol
Drug: Paricalcitol

First Posted Date: 2013-09-11

Last Posted Date: 2018-11-19

Lead Sponsor: Fundación Senefro

Target Recruit Count: 148

Registration Number: NCT01939977

Locations: 🇪🇸
Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain
🇪🇸
Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
🇪🇸
Hospital Puerta Del Mar, Cádiz, Spain

and more 13 locations

Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Paricalcitol, atorvastatin
Drug: Paricalcitol
Drug: Atorvastatin

First Posted Date: 2013-03-29

Last Posted Date: 2018-08-24

Lead Sponsor: Ricardo Mouzo Mirco

Target Recruit Count: 31

Registration Number: NCT01820767

Locations: 🇪🇸
Hospital El Bierzo. Servicio de Nefrología., Ponferrada, (León)., Spain
🇪🇸
Hospital de León, León, Spain

Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease

Not Applicable

Conditions: Type 2 Diabetes
Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: Zemplar

First Posted Date: 2013-02-15

Last Posted Date: 2013-02-15

Lead Sponsor: Scott and White Hospital & Clinic

Target Recruit Count: 60

Registration Number: NCT01792206

Locations: 🇺🇸
Tulane University, New Orleans, Louisiana, United States
🇺🇸
Omaha VA Medical Center, Omaha, Nebraska, United States
🇺🇸
Joslin Diabetes Clinic, Inc., Boston, Massachusetts, United States

and more 1 locations

Paricalcitol Effect on Anemia in CKD

Phase 4

Completed

Conditions: Anemia
Chronic Kidney Disease

Interventions: Drug: Calcitriol
Drug: Paricalcitol

First Posted Date: 2013-01-15

Last Posted Date: 2014-07-30

Lead Sponsor: Federico II University

Target Recruit Count: 60

Registration Number: NCT01768351

Locations: 🇮🇹
Federico II University, Naples, Italy

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

Phase 4

Terminated

Conditions: Kidney Failure
Secondary Hyperparathyroidism
Hyperphosphatemia
Hypercalcemia

Interventions: Drug: Calcitriol
Drug: Paricalcitol

First Posted Date: 2012-11-12

Last Posted Date: 2023-11-07

Lead Sponsor: Winthrop University Hospital

Target Recruit Count: 16

Registration Number: NCT01725113

Locations: 🇺🇸
Winthrop University Hospital, Mineola, New York, United States

Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria

Phase 3

Completed

Conditions: Proteinuria

Interventions: Drug: Paricalcitol

First Posted Date: 2012-09-27

Last Posted Date: 2016-03-30

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 77

Registration Number: NCT01694160

Locations: 🇳🇴
Renal Section, Oslo University Hospital, Rikshospitalet, Oslo, Norway

The Effects of Active VItamin D on Left Atrial Volume Index

Not Applicable

Withdrawn

Conditions: Heart Failure

Interventions: Drug: Paricalcitol

First Posted Date: 2012-06-28

Last Posted Date: 2013-08-16

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT01630408

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients

Phase 4

Completed

Conditions: Moderate to Severe Secondary Hyperparathyroidism
Stage 5 Chronic Kidney Diseases

Interventions: Drug: Paricalcitol
Drug: Darbepoetin alfa

First Posted Date: 2012-01-10

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 65

Registration Number: NCT01506947

Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients

Phase 3

Completed

Conditions: Disorder of Transplanted Kidney
Proteinuria
Albuminuria

Interventions: Drug: Placebo
Drug: Paricalcitol

First Posted Date: 2011-09-20

Last Posted Date: 2017-12-27

Lead Sponsor: University Medical Centre Ljubljana

Target Recruit Count: 168

Registration Number: NCT01436747

Locations: 🇸🇮
University Medical Centre Ljubljana, Ljubljana, Slovenia

Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Other: placebo
Drug: Paricalcitol

First Posted Date: 2011-07-13

Last Posted Date: 2017-03-03

Lead Sponsor: Mario Negri Institute for Pharmacological Research

Target Recruit Count: 112

Registration Number: NCT01393808

Locations: 🇮🇹
Azienda Ospedaliera Bolognini - Unità di Medicina, Seriate, BG, Italy
🇮🇹
Clinical Research Center fo Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy
🇮🇹
ASL of Ponte San Pietro - Diabetologic Unit, Brembate, Bergamo, Italy

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy